Melvin Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Melvin Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,442,700	Closed	-$89.5M	–	108
2020 Q4	$89.5M	Buy	1,442,700 +480,900	+50%	+$27.4M	0.38%	64
2020 Q3	$57.2M	Buy	961,800 +320,600	+50%	+$21.9M	0.29%	64
2020 Q2	$44.7M	Sell	641,200 -270,106	-30%	-$17.1M	0.26%	62
2020 Q1	$41.3M	Buy	911,306 +430,406	+90%	+$24.4M	0.33%	54
2019 Q4	$31.3M	Sell	480,900 -320,600	-40%	-$21.4M	0.26%	69
2019 Q3	$49.8M	Buy	+801,500	New	+$50.3M	0.4%	56

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return